Reflect on the provided data and tweets to anticipate if the closing price of $bmy is going to increase or decrease at 2017-02-14. Kindly respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-01-31,-1.5,0.5,-1.9,1.0,1.0,-1.6,2.1,6.8,10.4,12.2,13.3
2017-02-01,-0.3,0.1,-2.0,0.3,0.3,-1.9,0.4,5.1,9.1,11.1,12.4
2017-02-02,-2.3,0.8,-2.4,2.5,2.5,-2.8,-3.0,1.7,5.7,7.7,9.2
2017-02-03,-0.4,0.3,-0.8,0.6,0.6,-2.2,-3.2,0.4,4.2,6.6,8.0
2017-02-06,-0.8,0.1,-0.9,0.5,0.5,-1.7,-3.5,-0.8,2.8,5.4,7.0
2017-02-07,-0.3,1.3,-0.8,1.2,1.2,-1.9,-4.1,-2.6,0.7,3.7,5.3
2017-02-08,-1.4,0.2,-1.7,0.7,0.7,-1.5,-4.3,-3.7,-0.7,2.4,4.1
2017-02-09,1.0,1.4,-0.1,-0.9,-0.9,-0.2,-2.5,-3.3,-0.3,2.8,4.6
2017-02-10,-0.1,0.6,-0.3,0.3,0.3,-0.2,-2.0,-3.3,-1.0,1.9,3.9
2017-02-13,-0.4,0.1,-0.8,0.7,0.7,-0.5,-2.1,-3.7,-2.1,0.5,2.8

2017-01-31: 2/1 wl $drys $catb $mnta $aezs $tenx $fb $tsla $dis $jnug $dcix $ua $bmy $nugt $jdst $s $bac $nymt $ebay $pypl sham¡­ |scan results - 1,2,3 retracement bearish today: $bt $vivo $bmy $prgo $mnk ... |#b
2017-02-01: rt AT_USER $bmy just said it assumes $mrk will be successful in getting keytruda + chemo combo approval on keynote-021|$mjn  ..  vulnerable and gone ............  $bmy  is in same fix ....|rt AT_USER 
2017-02-02: $bmy: bristol-myers confirms fda approval for opdivo (nivolumab) in previously treated locally advanced or... |the AT_USER granted accelerated approval to #nivolumab (opdivo, $bmy company) for treatme
2017-02-03: bristol-myers squibb company forecasted to earn fy2018 earnings of $3.29 per share $bmy |bristol-myers squibb company forecasted to earn fy2018 earnings of $3.29 per share $bmy |is now a good time to 
2017-02-06: rt AT_USER clinical characteristics, healthcare costs &amp; resource utilization in #hcv vary by genotype¡ú #hepc #¡­|rt AT_USER $bmy jana partners report new stake|$bmy bristol-myers partner innate c
2017-02-07:  alerted another winner. must see track record &amp; subscribe  $jah $clr $dis $mo $bmy $pot| members have an advantage. see track record &amp; join  $dow $jah $clr $dis $mo $bmy|long term value plays
2017-02-08: eagle global advisors llc has $232,000 position in bristol-myers squibb company $bmy |bristol-myers squibb company $bmy position maintained by commonwealth bank of australia |fy2017 eps estimates for 
2017-02-09: 3-6 week outlook - short $dis long $bmy $tlt $twtr and expect a 5-8% correction in all major indicies. rates seem stable, wanna buy a house?|man...i've been wanting to do something in $bmy, but the st
2017-02-10: bristol-myers squibb company¡¯s $bmy buy rating reaffirmed at gabelli |bristol-myers squibb company¡¯s $bmy buy rating reaffirmed at gabelli |AT_USER AT_USER russ plumb's last co a littleknown antivir
2017-02-11: rt AT_USER AT_USER AT_USER AT_USER topline data #asco possible buyout of $nwbo by $bmy $mrk $azn $gild $celg ht¡­|AT_USER we like $bmy|rt AT_USER AT_USER AT_USER AT_USER topline data #asco possible bu
2017-02-12: if $ibb can start moving, $gild $bmy (beaten names, which have offered fake bounce in the last few months )are on radar|rt AT_USER pharma stocks getting clobbered.. great buying opportunity for the lo
2017-02-13: #bristolmyerssquibb better buy: exelixis, inc. vs. bristol-myers squibb. read more:  $bmy|#bristolmyerssquibb better buy: exelixis, inc. vs. bristol-myers squibb. read more:  $bmy|need help finding mo
Answer:
Reflect on the provided data and tweets to anticipate if the closing price of $bmy is going to increase or decrease at 2017-02-14. Kindly respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-01-31,-1.5,0.5,-1.9,1.0,1.0,-1.6,2.1,6.8,10.4,12.2,13.3
2017-02-01,-0.3,0.1,-2.0,0.3,0.3,-1.9,0.4,5.1,9.1,11.1,12.4
2017-02-02,-2.3,0.8,-2.4,2.5,2.5,-2.8,-3.0,1.7,5.7,7.7,9.2
2017-02-03,-0.4,0.3,-0.8,0.6,0.6,-2.2,-3.2,0.4,4.2,6.6,8.0
2017-02-06,-0.8,0.1,-0.9,0.5,0.5,-1.7,-3.5,-0.8,2.8,5.4,7.0
2017-02-07,-0.3,1.3,-0.8,1.2,1.2,-1.9,-4.1,-2.6,0.7,3.7,5.3
2017-02-08,-1.4,0.2,-1.7,0.7,0.7,-1.5,-4.3,-3.7,-0.7,2.4,4.1
2017-02-09,1.0,1.4,-0.1,-0.9,-0.9,-0.2,-2.5,-3.3,-0.3,2.8,4.6
2017-02-10,-0.1,0.6,-0.3,0.3,0.3,-0.2,-2.0,-3.3,-1.0,1.9,3.9
2017-02-13,-0.4,0.1,-0.8,0.7,0.7,-0.5,-2.1,-3.7,-2.1,0.5,2.8

2017-01-31: 2/1 wl $drys $catb $mnta $aezs $tenx $fb $tsla $dis $jnug $dcix $ua $bmy $nugt $jdst $s $bac $nymt $ebay $pypl sham¡­ |scan results - 1,2,3 retracement bearish today: $bt $vivo $bmy $prgo $mnk ... |#b
2017-02-01: rt AT_USER $bmy just said it assumes $mrk will be successful in getting keytruda + chemo combo approval on keynote-021|$mjn  ..  vulnerable and gone ............  $bmy  is in same fix ....|rt AT_USER 
2017-02-02: $bmy: bristol-myers confirms fda approval for opdivo (nivolumab) in previously treated locally advanced or... |the AT_USER granted accelerated approval to #nivolumab (opdivo, $bmy company) for treatme
2017-02-03: bristol-myers squibb company forecasted to earn fy2018 earnings of $3.29 per share $bmy |bristol-myers squibb company forecasted to earn fy2018 earnings of $3.29 per share $bmy |is now a good time to 
2017-02-06: rt AT_USER clinical characteristics, healthcare costs &amp; resource utilization in #hcv vary by genotype¡ú #hepc #¡­|rt AT_USER $bmy jana partners report new stake|$bmy bristol-myers partner innate c
2017-02-07:  alerted another winner. must see track record &amp; subscribe  $jah $clr $dis $mo $bmy $pot| members have an advantage. see track record &amp; join  $dow $jah $clr $dis $mo $bmy|long term value plays
2017-02-08: eagle global advisors llc has $232,000 position in bristol-myers squibb company $bmy |bristol-myers squibb company $bmy position maintained by commonwealth bank of australia |fy2017 eps estimates for 
2017-02-09: 3-6 week outlook - short $dis long $bmy $tlt $twtr and expect a 5-8% correction in all major indicies. rates seem stable, wanna buy a house?|man...i've been wanting to do something in $bmy, but the st
2017-02-10: bristol-myers squibb company¡¯s $bmy buy rating reaffirmed at gabelli |bristol-myers squibb company¡¯s $bmy buy rating reaffirmed at gabelli |AT_USER AT_USER russ plumb's last co a littleknown antivir
2017-02-11: rt AT_USER AT_USER AT_USER AT_USER topline data #asco possible buyout of $nwbo by $bmy $mrk $azn $gild $celg ht¡­|AT_USER we like $bmy|rt AT_USER AT_USER AT_USER AT_USER topline data #asco possible bu
2017-02-12: if $ibb can start moving, $gild $bmy (beaten names, which have offered fake bounce in the last few months )are on radar|rt AT_USER pharma stocks getting clobbered.. great buying opportunity for the lo
2017-02-13: #bristolmyerssquibb better buy: exelixis, inc. vs. bristol-myers squibb. read more:  $bmy|#bristolmyerssquibb better buy: exelixis, inc. vs. bristol-myers squibb. read more:  $bmy|need help finding mo
Answer:+Rise